AYTU vs. LTRN, CKPT, ANVS, BTAI, VHAQ, RLYB, BLRX, MNOV, ELDN, and AFMD
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Lantern Pharma (LTRN), Checkpoint Therapeutics (CKPT), Annovis Bio (ANVS), BioXcel Therapeutics (BTAI), Viveon Health Acquisition (VHAQ), Rallybio (RLYB), BioLineRx (BLRX), MediciNova (MNOV), Eledon Pharmaceuticals (ELDN), and Affimed (AFMD). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Lantern Pharma has a net margin of 0.00% compared to Aytu BioPharma's net margin of -14.60%. Aytu BioPharma's return on equity of -31.31% beat Lantern Pharma's return on equity.
33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 2.8% of Aytu BioPharma shares are held by insiders. Comparatively, 6.9% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Aytu BioPharma received 243 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 67.11% of users gave Aytu BioPharma an outperform vote.
Lantern Pharma has lower revenue, but higher earnings than Aytu BioPharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lantern Pharma had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for Lantern Pharma and 2 mentions for Aytu BioPharma. Lantern Pharma's average media sentiment score of 0.72 beat Aytu BioPharma's score of 0.43 indicating that Lantern Pharma is being referred to more favorably in the news media.
Aytu BioPharma currently has a consensus target price of $5.00, indicating a potential upside of 58.73%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aytu BioPharma is more favorable than Lantern Pharma.
Aytu BioPharma has a beta of -1.23, meaning that its stock price is 223% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Summary
Aytu BioPharma beats Lantern Pharma on 9 of the 17 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
